Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and Above

PHASE3CompletedINTERVENTIONAL

Enrollment

121

Participants

Timeline

Start Date

April 29, 2015

Primary Completion Date

June 3, 2015

Study Completion Date

June 3, 2015

Conditions

Influenza

Interventions

BIOLOGICAL

Fluarix Tetra

One dose of the Fluarix™ Tetra vaccine was administered to all subjects on Day 0 (Visit 1) intramuscularly into the deltoid of the non-dominant arm.

Trial Locations (2)

GSK Investigational Site, Belo Horizonte

GSK Investigational Site, São Paulo